IMUC (EOM Pharmaceutical Holdings) Scaled Net Operating Assets: 0.11 (As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Scaled Net Operating Assets?

EOM Pharmaceutical Holdings IMUC Scaled Net Operating Assets is 0.11 as of Jun. 2018.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

EOM Pharmaceutical Holdings's operating assets for the quarter that ended in Jun. 2018 was $0.98 Mil. EOM Pharmaceutical Holdings's operating liabilities for the quarter that ended in Jun. 2018 was $0.40 Mil. EOM Pharmaceutical Holdings's Total Assets for the quarter that ended in Mar. 2018 was $5.17 Mil. Therefore, EOM Pharmaceutical Holdings's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2018 was 0.11.


EOM Pharmaceutical Holdings Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Scaled Net Operating Assets Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 0.00 -0.04 -0.18 -0.12

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -1.36 -0.29 -0.19 0.11

IMUC vs MNTMD, RTTR, BZYR: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Scaled Net Operating Assets falls into.



EOM Pharmaceutical Holdings Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

EOM Pharmaceutical Holdings's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2017 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2017 )
=(Operating Assets (A: Dec. 2017 )-Operating Liabilities (A: Dec. 2017 ))/Total Assets (A: Dec. 2016 )
=(0.379-2.361)/16.89
=-0.12

where

Operating Assets(A: Dec. 2017 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=7.009 - 6.63
=0.379

Operating Liabilities(A: Dec. 2017 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.361 - 0 - 0
=2.361

EOM Pharmaceutical Holdings's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2018 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2018 )
=(Operating Assets (Q: Jun. 2018 )-Operating Liabilities (Q: Jun. 2018 ))/Total Assets (Q: Mar. 2018 )
=(0.976-0.402)/5.165
=0.11

where

Operating Assets(Q: Jun. 2018 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.829 - 2.853
=0.976

Operating Liabilities(Q: Jun. 2018 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.402 - 0 - 0
=0.402

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.11 mean?
EOM Pharmaceutical Holdings (IMUC) has a Scaled Net Operating Assets of 0.11 as of Jun. 2018. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Scaled Net Operating Assets too high?
EOM Pharmaceutical Holdings' current Scaled Net Operating Assets is 0.11.
How does EOM Pharmaceutical Holdings' Scaled Net Operating Assets compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Scaled Net Operating Assets of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Scaled Net Operating Assets is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Scaled Net Operating Assets of 0.11. The current Scaled Net Operating Assets is 0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Scaled Net Operating Assets is 0.11 as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.